SL Science Holding completes business combination, lists on Nasdaq as SLBT
SL Science Holding Limited announced the completion of its business combination with SL BIO Ltd. and Horizon Space Acquisition II Corp. The newly formed entity, SL Science Holding Limited, is set to begin trading its ordinary shares on the Nasdaq Global Market under the ticker "SLBT" on June 15, 2026. This transaction, which implies an equity valuation of SL Bio at approximately $5.568 billion and included a $7.8 million PIPE financing, provides strategic capital to accelerate the development of its proprietary Gamma delta T cell-based cellular therapies for solid tumor indications. The company has also bolstered its leadership team and board of directors to support its strategic growth and compliance as a U.S.-listed public entity.
Key Highlights
- SL Science Holding Limited completed its business combination with SL BIO Ltd. and Horizon Space Acquisition II Corp.
- The company's ordinary shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "SLBT" on June 15, 2026.
- The business combination implies an equity valuation of SL Bio at approximately $5.568 billion.
- A concurrent PIPE financing of $7.8 million was also closed.
- The capital will advance SL Bio's Gamma delta T cell-based therapies for solid tumor indications, including pancreatic and brain cancers.
- SL Science has formalized an expanded executive leadership team and Board of Directors.
Price Impact